Antengene Corporation Ltd
HKEX:6996
Antengene Corporation Ltd
Interest Income Expense
Antengene Corporation Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
Interest Income Expense
¥87.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
106%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Interest Income Expense
¥1.1B
|
CAGR 3-Years
52%
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Interest Income Expense
¥145.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
23%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Interest Income Expense
¥472.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
21%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Interest Income Expense
¥958.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Interest Income Expense
¥65.5m
|
CAGR 3-Years
41%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's Interest Income Expense?
Interest Income Expense
87.2m
CNY
Based on the financial report for Dec 31, 2023, Antengene Corporation Ltd's Interest Income Expense amounts to 87.2m CNY.
What is Antengene Corporation Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
106%
Over the last year, the Interest Income Expense growth was -69%.
You don't have any saved screeners yet